Efficacy of PreOperative Bevacizumab for Diabetic Eye Disease

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Reports of the use of intravitreal bevacizumab (Avastin, Genentech) for the reduction of neovascularization in proliferative diabetic retinopathy have demonstrated significant regression in the number of new vessels. Reducing the vascularity of neovascular fibrovascular tissue can potentially reduce bleeding intraoperatively and thus facilitate the vitrectomy procedure. The investigators chose to investigate the potential benefit of the use of preoperative bevacizumab in the management of these most complex cases.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Tractional Retinal Detachment involving or threatening the macula,

• Tractional+Rhegmatogenous Retinal Detachment, or

• Fibrovascular tissue covering and distorting the macula.

Exclusion Criteria:

• Vitrectomy

• Neovascular glaucoma

• Dense media opacity (dense cataract and vitreous hemorrhage) precluding fluorescein angiography (FA)